Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists


259 E Grand Avenue #3434
South San Francisco, CA 94080
Website Company Summary Management Team

CEO: Mike Nolan (5/31/2019)
President/COO/Operations: Riley Ennis (1/31/2014)
General Management: Linda McAllister (6/30/2019) ; Adam Drake (12/31/2015) ; Girish Putcha (7/31/2016)
Finance: William Quirk (6/1/2020)
Technology: Jimmy Lin (4/30/2019)
Sales/Marketing: Charles Roberts
HR: Tony Park
General Counsel/Legal: April Wurster ; Beverly Dale
Former Employees: Gabriel Otte Lisa Cheng Michael Otte

Outside board: (May no longer be on the board) Vijay Pande (a16z General Partner)

Business description: Freenome is a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection. By combining a deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, Freenome is developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Examples of Freenome’s novel research include advancing the fields understanding of using machine learning for early stage colorectal cancer detection featured at Digestive Disease Week and using cfDNA fragment coverage to predict gene expression featured at American Association for Cancer Research’s Annual Meeting. Freenome is headquartered in South San Francisco, California. For more information about Freenome, visit and view open positions at

Rounds: 5
Recent Fundings: Aug 2020   Jul 2019
Capital raised: 507.5M
Last Round: 270.0M
Ownership: Private  
VCs include: Asset Management VenturesCRVFarallon Capital Management Founders Funda16zInnovation EndeavorsDCVCAME Cloud Ventures;  RA Capital Management ;  Rock Springs Capital ;  Fidelity Management & Research Cormorant Asset Management s28 Capital;  Allen & Co.;  Third Kind Venture Capital ;  Section 32 ;  Bain Capital Life Sciences Perceptive Advisors ;  Janus Henderson Investors ;  BrightEdge Ventures ;  Catalio Capital Management ;  Colorectal Cancer Alliance EcoR1 Capital
Corporate investors: Kaiser Permanente Ventures ;  Roche Venture Fund GVAlphabet
Private equity: T. Rowe Price

Last Tweets


Last Mentions

Record updated: Jul 2021
Sector: Biotech
Year Founded: 2014
Headcount: 201-300 as of Jun 2021
Rounds: 5
Recent Fundings: Aug 2020   Jul 2019
Capital Raised: 507.5M
Last Round: 270.0M
Ownership: Private